Sp119
ESOPHAGUS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are. Furthermore, the attendees will receive information on how to interpret results from these tests.
This session will have six talks on the indications, limitations, procedural and technical aspects on clinically useful GI physiology tests. The attendees will learn for which patients these test can be of value, and what type of results you can expect and how reliable these are. Furthermore, the attendees will receive information on how to interpret results from these tests.
Presenter
Amsterdam UMC, University of Amsterdam
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTERIM RESULTS FROM A FIRST-IN-HUMAN STUDY OF THE ANTI-IL-15 ANTIBODY CALY-002 FOR TREATING CELIAC DISEASE AND EOSINOPHILIC ESOPHAGITIS
INTRODUCTION Interleukin-15 (IL-15) is an important cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses…
EPIDEMIOLOGIC BURDEN AND PROJECTIONS FOR EOSINOPHILIC ESOPHAGITIS-ASSOCIATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES (2009-2030)
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
DUPILUMAB IMPROVES HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS, REGARDLESS OF PRIOR HISTORY OF ESOPHAGEAL DILATION
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
